Sen­ate Fi­nance Chair Ron Wyden is ask­ing Am­gen again for more in­for­ma­tion on its fi­nan­cials as he con­tin­ues to dig in­to the way phar­ma com­pa­nies use sub­sidiaries in low- or ze­ro-tax coun­tries to low­er their bills.

The De­mo­c­rat sen­a­tor from Ore­gon said to­day that he sent Am­gen a fi­nal re­quest for “vol­un­tary com­pli­ance” to pro­vide spe­cif­ic in­for­ma­tion on Am­gen’s fi­nan­cials. The let­ter, ad­dressed to Am­gen CEO Robert Brad­way, asked him to ex­plain how Am­gen paid a low­er tax rate than the stan­dard cor­po­rate tax rate in the US of 21%.

“Am­gen paid an ef­fec­tive tax rate of 12.1 per­cent in 2018, 14.2 per­cent in 2019, 10.7 per­cent in 2020 and 12.1 per­cent in 2021,” Wyden wrote.

The sen­a­tor’s let­ter al­so not­ed that the sen­a­tor is look­ing at sales of En­brel, an Am­gen arthri­tis drug that booked more than $4 bil­lion in US sales last year. The let­ter con­tin­ues, claim­ing that in­come from En­brel and oth­er drugs ap­pears to be re­port­ed in coun­tries out­side the US for tax pur­pos­es.

More specif­i­cal­ly, Wyden said that Am­gen gen­er­at­ed 70% of its over­all sales in the US, yet on­ly re­port­ed 28% of pre-tax in­come in the US.

It was al­so not­ed that the IRS is claim­ing that Am­gen moved $24 bil­lion in in­come to en­ti­ties in Puer­to Ri­co to save sev­er­al bil­lion dol­lars in US fed­er­al tax­es. The WSJ re­port­ed ear­li­er this year that the fed­er­al agency is look­ing to have Am­gen pay $10.7 bil­lion in back tax­es and penal­ties.

Am­gen caught Wyden’s eye af­ter he sent a let­ter to the phar­ma back in Au­gust and asked for in­for­ma­tion on its fi­nan­cials in his con­tin­u­ing in­ves­ti­ga­tion that has touched oth­er phar­ma com­pa­nies too — in­clud­ing the likes of Mer­ck, Ab­b­Vie and Bris­tol My­ers Squibb.

“While Am­gen re­spond­ed to the Au­gust let­ter and has en­gaged with the com­mit­tee, it re­fused to pro­vide spe­cif­ic in­for­ma­tion re­lat­ed to pre-tax earn­ings, prof­it mar­gins, and tax paid in the Unit­ed States,” Wyden’s of­fice said in a state­ment Thurs­day.

Wyden is ask­ing Am­gen for a litany of spe­cif­ic tax da­ta, in­clud­ing break­downs of pre-tax earn­ings and agree­ments with Puer­to Ri­co en­ti­ties, by De­cem­ber 21.

An Am­gen spokesper­son tells End­points News that “Am­gen has co­op­er­at­ed vol­un­tar­i­ly with the Com­mit­tee’s re­quests and re­mains com­mit­ted to work­ing with the Com­mit­tee sub­ject to ap­pro­pri­ate treat­ment of its con­fi­den­tial tax in­for­ma­tion. Be­cause Am­gen is cur­rent­ly in lit­i­ga­tion with the In­ter­nal Rev­enue Ser­vice (IRS), there are lim­i­ta­tions on the in­for­ma­tion the com­pa­ny can pro­vide. More­over, much—if not all—of the in­for­ma­tion re­quest­ed is avail­able to the Com­mit­tee through ap­pro­pri­ate process, as en­act­ed by Con­gress.”

President Joe Biden made clear in his “finish the job” State of the Union address last night that one of those jobs to be finished is insulin prices.

Biden’s push again to tackle insulin prices, after Republicans rebuffed the idea last summer and just after Biden won Medicare drug price negotiations/caps via the Inflation Reduction Act, shows how heavily he’s leaning into this work.

Six weeks into his new role at the helm of Teva Pharmaceutical, Richard Francis said it’s time to “get back to growth,” starting with a good look at the company’s priorities.

The chief executive has kicked off a strategic review, he announced during Teva’s quarterly call, which will continue over the next several months and produce results sometime in the middle of 2023. That means some pipeline cuts may be in store, he told Endpoints News, while declining to offer much more detail.

We now know where Roche’s ex-pharma chief Bill Anderson is going.

German pharma giant Bayer announced Wednesday that Anderson will be taking on the role as CEO, less than six weeks after Anderson stepped down from his perch at Roche as head of the group’s pharmaceutical division.

Roche announced back in December that Anderson would depart on Dec. 31 to “pursue opportunities outside of Roche.” His replacement, Genentech vet and Roche’s current head of global product strategy, Teresa Graham, will start her role in March.

The DC Circuit Court has struck a blow against the pharmaceutical lobbying group PhRMA and other plaintiffs’ attempt to stop states from importing drugs from Canada.

Joined alongside public health group Partnership for Safe Medicines and advocacy group Council for Affordable Health Coverage, PhRMA was rebuffed by Judge Timothy Kelly on Monday, who dismissed the civil suit due to a lack of standing.